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PERSISTENT INFECTIONS IN CHRONIC CHAGAS’ DISEASE PATIENTS TREATED WITH
ANTI-Trypanosoma cruzi NITRODERIVATIVES
M. Socorro BRAGA, Liana LAURIA-PIRES, Enrique R. ARGAÑARAZ, Rubens J. NASCIMENTO & Antonio R. L. TEIXEIRA
SUMMARY
We used a molecular method and demonstrated that treatment of the chronic human Trypanosoma cruzi infections with
nitroderivatives did not lead to parasitological cure. Seventeen treated and 17 untreated chronic Chagas’ disease patients, with at least
two out of three positive serologic assays for the infection, and 17 control subjects formed the study groups. PCR assays with nested
sets of T. cruzi DNA primers monitored the efficacy of treatment. The amplification products were hybridized to their complementary
internal sequences. Untreated and treated Chagas’ disease patients yielded PCR amplification products with T. cruzi nuclear DNA
primers. Competitive PCR was conducted to determine the quantity of parasites in the blood and revealed < 1 to 75 T. cruzi/ml in
untreated (means 25.83 ± 26.32) and < 1 to 36 T. cruzi/ml in treated (means 6.45 ± 9.28) Chagas’ disease patients. The difference
between the means was not statistically significant. These findings reveal a need for precise definition of the role of treatment of
chronic Chagas’ disease patients with nitrofuran and nitroimidazole compounds.
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INTRODUCTION
Recent publications have described notable advances in experimental
chemotherapy of the T. cruzi infections, and results obtained with specific
therapeutic regimes have been considered satisfactory6,27,28. The sterol
and phospholipid synthesis inhibitors, which have been synthesized as
anti-fungal drugs, and produced 70 to 90% cure of the experimental
murine infections, did not prove to be effective in the treatment of human
Chagas’ disease28. In addition, synthesis of a novel chemical class of 60
nitrobenzofurans designed for advantageous activity against the murine
T. cruzi infections yielded a single compound 1.6 times as effective than
the reference drug nifurtimox13. However, several authors have shown
the nitrobenzofurans and related compounds bear high potential for
mutagenesis, carcinogenesis, teratogenesis and sterility4,18,21-23,25.
Itraconazol used as an anti-fungal drug for 20 years, produced
parasitologic cure in 53% of chronic Chagas’ disease patients (6mg/kg/
day, for 60 days) whereas allopurinol (8.5 mg/kg/day) yielded
parasitologic cure in 44% of treated Chagas’ disease patients2. The
treatment of acute T. cruzi-infected patients with benznidazole resulted
in conversion of serologic assays, which was considered equivalent to
parasitological cure in 60% to 20% of treated cases1,15. However, the
dichotomy between responders and non-responders of the specific drug
therapy needs to be explained, since treatment did not appear to influence
the clinical features of the acute infection12,15. Broad discrepancies in
percentage of parasitological cure of chronic infections have been
reported but they were explained by sectional observations, conducted
on different occasions after treatment, in which the patients were not
protected against the reduvid insect-vector and, therefore, the possibility
of superinfection can not be ruled out8-11,14-16,29.
In the absence of new drugs, nitroimidazol and nitrofuran are the
compounds used to treat human Chagas’ disease8,9,29. Here we present
results of a study of chronic Chagas patients treated with benznidazole
(N-benzyl-2-nitro-1-imidazolacetamide) or nifurtimox (4-[5-nitro-3-
methyl-furfurylideneanimo]-tetrahydro-4-H-1,4-thiazine-1-1-dioxide).
This study conducted in an insect-vector transmission-free urban area
shows persistence of the T. cruzi infection in each Chagas patient,
regardless of treatment.
MATERIALS AND METHODS
Study population
This study was conducted at the Medical Offices of the Brasília
Refuse Department, and at the Chagas’ Disease Multidisciplinary
Research Laboratory, University of Brasília. The study protocol was
approved by the Institutional Ethical Committee in Human Research.
The street-cleaners enrolled in the programme gave written consent to
participate in the study.
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Serologic assays
Each street-cleaner was subjected to immunological assays to
determine specific antibodies for the T. cruzi infection. Patients showing
at least two out of three positive tests (ELISA, indirect
immunofluorescence [IF] and indirect hemagglutination [IH]26 were
considered T. cruzi infected30. The results of the serological study in this
series were validated by ELISA, IF and IH assays run in parallel with a
panel of sera from 94 Chagas’ disease patients with parasitological
demonstration of T. cruzi24.
Xenodiagnosis
This test was performed in each patient with positive immunological
tests for the infection, essentially as described22.
Study groups
The street-cleaners enrolled in this programme were subjected to
immunological assays and 18.5% of them showed serological evidence
of T. cruzi infections26. A cohort of these Chagas patients were treated
with anti-trypanosomal nitrofuran or nitroimidazole (10 mg/kg/day, per
os), because they showed severe electrocardiographic alterations. Among
treated Chagas patients we selected 17 who had completed full treatment
for 30 days or above. These treated patients were matched by gender
and age with 17 untreated Chagas patients and with 17 control, non-
Chagas individuals. As a result, three study groups were formed
comprising 51 male street-cleaners: i) treated; ii) untreated; iii) control,
with serologic tests negative for the T. cruzi infection.
Polimerase chain reaction (PCR) and hybridization
DNA samples extracted from 10 ml of peripheral blood from each
street-cleaner were analysed by PCR with specific primers for the constant
regions of minicircles of kinetoplast DNA (kDNA) and to highly
repetitive sequences of nuclear DNA (nDNA) of T. cruzi 3, 17, 19 . The kDNA
primer set (S35, 5'-ATAATGTACGGG(T/G)GAGATGC-3' and S36, 5'-
GGTTCGATTGGGGTTGGTG-3') annealing to the constant region of
minicircles yields a 330 bp product and its catamer of 660 bp19. The
nDNA primer set (PON1, 5'-TGGCTTGGAGGAGTTATTGT-3' and
PON2, 5'-AGGAGTGACGGTTGATCAGT-3') amplifies a 250 bp
fragment17. A DNA thermal cycler (MJ Research, Watertown, MA) was
used for 30-32 cycles, as described7. Negative controls (water and
P388D1-IL1 DNA) and positive control (T. cruzi DNA) were always
included to detect DNA contamination and ensure that the PCR worked
efficiently. The PCR amplification products were transferred by capillarity
to a nylon membrane. Prehybridization and hybridization were performed
as described7. For S35/36 products, the sequence was S67 5'-
GGTTTTGGGAGGGG(CG)-(G/C)-(T/G)TC-3'19. For PON1/2 products,
the sequence was PON3 5'-CCGGCCTGTGTCTGCGGC-3'17. These
oligonucleotides were radiolabelled with [(α 32P]-dATP (3000 CimMol)
using the polynucleotide kinase method following the manufacturer’s
recommendation (Life Technologies).
Competition assays
These assays were conducted in blood samples of 17 untreated and
of 17 treated Chagas patients who had received full treatment with
nitroderivatives for 30 days and above. DNA samples from all these
serologically positive patients that yielded positive PCR amplification
products of the size expected with specific kDNA and nDNA primers
were used for quantification of the parasitemia, as described7.
Statistical analysis
The results are presented as means and standard deviation. The
Student t test was used for group analysis.
RESULTS
Regardless of chemotherapeutic regime used, all Chagas’ disease
patients showed at least two out of three positive tests (ELISA, IF and
IH) for the T. cruzi infections. Furthermore, the quantitative serological
assays showed antibody titers in the treated Chagas group to be as high
as those for the untreated Chagas patients (data not shown). No subject
in the control group showed positive serology. Furthermore, we took
advantage of results of xenodiagnosis showing parasitological
demonstration of T. cruzi infections in chronic Chagas patients and used
blood samples from these patients for covalidation of data obtained with
serological and PCR assays. Results of these experiments are shown in
Table 1.
Each Chagas patient yielded PCR amplification products with
specific primers that annealed to T. cruzi nDNA (Figure 1). All these
Chagas patients had shown PCR amplification product that formed a
predictable size band in agarose gels, when specific kDNA primers were
Table 1
Covalidation of serological and PCR assays in blood samples of seven
Chagas’ disease patients with Trypanosoma cruzi demonstration by
xenodiagnosis
Patienta) Seropo- PCRc)
Number sitivityb) Nuclear Kinetoplast Quantitative
DNA DNA
Untreated Chagas
patients
142 Pos Pos Pos 50
159 Pos Pos Pos 0.3
162 Pos Pos Pos 0.5
282 Pos Pos Pos 50
335 Pos Pos Pos 50
Treated Chagas
patients
201 Pos Pos Pos 3 x 104
1250 Pos Pos Pos 5
a)
 Eight Chagas patients had positive xenodiagnosis. One treated Chagas patient died before
DNA tests were performed.
b) Specific serum antibodies detected by immunofluorescence, hemagglutination and ELISA.
c)
 PCR amplification products with kDNA and nDNA primers hybridized to specific internal
sequences. The quantity of T. cruzi per ml of blood was determined by quantitative PCR, as
described elsewhere7
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used. This product was hybridized with its complementary internal
sequence. In contrast, none of the 17 control subjects, showing negative
serological assays, yielded PCR amplification products with specific
kDNA and nDNA primers.
The quantitative PCR was used to detect parasitemias in the blood
of 34 patients with chronic Chagas’ disease (Table 2). Among 17 Chagas
patients treated with nitroderivatives, 41% received the drug for 30 days
and 59% for 60 days. Citrated blood was collected from these patients
10 years after treatment. The competitive PCR assays showed T. cruzi
kDNA bands at various points of equivalency with the competitor DNA
bands, regardless of whether the template DNA was originated from
treated or untreated Chagas patients. The competitive PCR quantification
of T. cruzi in treated and untreated Chagas patients is shown in Table 2
and Figure 2. Seventeen untreated Chagas patients showed bands whose
intensity was compared to that of DNA from a known quantity of T.
cruzi showing equivalency in a range of < 1-to-75 parasites/ml of blood.
The average means of T. cruzi/ml in this group was 25.83 ± 26.32. In
addition, 16 treated Chagas patients showed bands whose equivalency
ranged from < 1-to-36 parasites/ml of blood. The average means in this
group was 6.45 ± 9.28. The statistical analysis demonstrated that the
differences of means of parasitemias between treated and untreated
Chagas patients are not significant. One treated Chagas patient (no 201)
showed exquisitely high number of parasites in the blood and was not
considered for statistical analysis.
DISCUSSION
The prescription of nitroderivatives to treat the T. cruzi infections of
street-cleaners with clinical and serological evidence of Chagas’ disease
was made by physicians at the Medical Offices of the Brasília Refuse
Department, Federal District of Brazil. The Federal District is insect-
Fig. 1 - A: PCR amplification of sequences of nDNA from Trypanosoma cruzi with specific
PON1/2 primers. Lane 1, 100 bp molecular weight marker; Lane 2, water (negative control);
Lane 3, P388D1-IL1 DNA; Lane 4, Chagas’ patient DNA; Lane 5, T. cruzi DNA. B: Southern
hybridization with an internal fragment of DNA complementary to the PCR amplification
product. Note the 250 bp bands in lanes 4 and 5 (see methods).
Fig. 2 - Quantitation of T. cruzi DNA in a treated Chagas patient by competitive PCR. Lane
1, molecular weight standard; Lanes 2-to-6, 1/50 aliquots of DNA extracted from a treated
Chagas patient and various quantities of competitor DNA: Lane 2, 150 fg; Lane 3, 15 fg;
Lane 4, 1.5 fg; Lane 5, 0.15 fg; Lane 6, 0 fg. Lane 7, water (negative control). These competitive
PCR assay consisted of mixing an unknown amount of template DNA (T. cruzi minicircle
DNA) with serial dilutions of a known quantity of competitor DNA (280 bp kDNA sequence
obtained by cloning in the p7Blue vector). The competitor fragment that binds to the kDNA
primers S35/36 yielded amplification product of a smaller size than that of the T. cruzi template
DNA (280 vs 330 bp). The point of equivalency between the 330 and the 280 bp bands was
given by tye tube showing equimolar concentration of template and of competitor DNAs in
the 1.5% agarose gel. The quantity of T. cruzi was then calculated by the concentration of
competitor DNA, assuming there are 10,000 minicircles/parasite and, therefore, 15 fg of 330
bp sequence/parasite7. This Figure illustrates the point of equivalency at 1.5 fg (Lane 4),
which is approximately the amount of DNA in 0.1 parasite.
Table 2
Competitive PCR quantification of Trypanosoma cruzi in the blood of treated
and untreated chronic Chagas’ disease patients*
Treated Chagas patients Untreated Chagas patients
Patient number T. cruzi/ml Patient number T. cruzi/ml
154 0.5 139 0.4
178 0.8 162 0.56
213 0.8 133 0.7
135 1.05 148 0.8
245 1.6 270 0.2
195 2.0 123 0.3
132 2.5 159 0.3
137 3.0 116 0.8
173 4.0 113 30.0
177 4.0 211 40.0
185 4.0 288 40.0
1250 5.0 157 40.0
707 8.0 142 50.0
136 10.0 335 50.0
175 20.0 282 50.0
 524† 36.0 144 60.0
 201† 3 x 104‡ 140 75.0
X ± SD 6.45 ± 9.28 X ± SD 25.83 ± 26.32
* The assays were performed as described in the legend of Figure 2.
†
 These patients underwent two series of nitroderivatives, each for 60 days.
‡
 Treated patient 201 with an absurbly high parasitemia was excluded from the group means.
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vector transmission-free of the T. cruzi infections and, therefore the
possibility of superinfections was ruled out in this study.
Records in the files of all individuals in the study groups have shown
that nitrofuran nifurtimox (10 mg/kg/day) was prescribed for 62% of
Chagas patients. Nitroimidazole benznidazole (10 mg/kg/day) was
prescribed to treat 38% of the remaining chagasic patients. In this series
we report only those cases of chronic Chagas’ disease undergoing full
treatment for at least 30 days and showing PCR amplifications with
specific kDNA and nDNA primers. In order to determine the efficacy of
nitroderivative chemotherapy of the T. cruzi infections therefore, we used
a quantitative PCR assay for detecting subclinical parasitemias in treated
and untreated chronic Chagas patients. In this regard, previously we had
run serological and quantitative PCR testings of blood samples from
patients with positive xenodiagnosis, which showed consistently positive
results. Essentially, the methods used were covalidated by these results.
Here we report that phenotypic and genotypic markers of the T. cruzi
infections, which were used to evalutate the efficacy of nitroderivative
therapy, did not shown significant differences in groups of treated and
untreated Chagas’ disease patients. In the first category, high titers of
specific antibodies were observed in treated as well as in untreated Chagas
patients. The lack of alteration of the serologic profile suggests that the
specific chemotherapy did not affect the humoral immune responses to
the parasitic antigens (data not shown). The discrepancy between these
observations and those reported in the literature1,9,11,12,15,29 might be
explained by the fact that we used a highly sensitive molecular method
to detect very low levels of parasitemias in treated and untreated chronic
Chagas’ disease patients. The persistence of T. cruzi shown in treated
Chagas patients in this series may not be considered as resulting of
reinfections, because our patients lived in an insect-vector transmission-
free area.
Genotypic markers of T. cruzi infections were present in the treated
as well as in the untreated chronic Chagas’ disease patients in this series.
We obtained PCR amplification products from Chagas’ disease patients
template DNA with nested sets of primers of nuclear DNA and kinetoplast
DNA of T. cruzi, regardless of the patient belonging to the treated or the
untreated group. In view of the observation that sequences of minicircles
of T. cruzi may integrate in the genome of the host cell, we suggested
that the nuclear DNA is the only genotypic marker that confers evidence
of the living T. cruzi infection in treated and in untreated Chagas’ disease
patients20. In this regard, we used template DNA from both groups of
Chagas’ disease patients who had shown PCR amplification products
with the primer set PON1/2, in order to quantify the parasitemia by
competitive PCR7,17.
The tests of competitive PCR were run with template DNA from 34
Chagas patients, treated and untreated, which have shown the 330 bp
band amplified with the S35/36 kDNA primers. This criteria secured
optimal amplification reactions and allowed comparison between the
280 bp band (amplification of the competitor DNA) and the 330 bp
(amplification of the sequence of the minicircle kDNA of T. cruzi). The
quantification of the minicircle DNA was determined at the tube of
equivalency with known concentration of the competitor DNA.
Considering that each parasite contains 15 fg of the 330 bp minicircle
sequence, the quantity of parasite in each ml of blood was determined7.
To our knowledge, this study shows, for the first time with a molecular
method, that the treatment of chronic Chagas’ disease patients with
nitrofuran and nitroimidazole compounds do not lead to the
parasitological cure of the T. cruzi infections.
The demonstration of persisting phenotypic and genotypic markers
of the living T. cruzi infections in patients treated with anti-trypanosomal
drugs indicates these drugs have limited efficacy. The results discussed
here show that assessment of cure after treatment of acute and chronic
Chagas’ disease requires a highly sensitive molecular method for
detecting subclinical parasitemias. Moreover, treatment of chronic
Chagas’ disease remains controversial10, therefore requiring further
research evaluation of benefits resulting from nitroderivative therapy5.
In this regard, new drugs without undesirable side effects are needed,
and that hopefuly promoting a true parasitological cure of the infection
would halt the progression of the chronic disease.
RESUMO
Persistência das infecções em pacientes chagásicos crônicos
tratados com nitroderivados anti-Trypanosoma cruzi
Usamos um método molecular e demonstramos que o tratamento de
infecções crônicas pelo Trypanosoma cruzi com nitroderivados, que se
mostraram eficientes em diminuir parasitemias nas infecções agudas,
não produziu cura parasitológica. Trinta e quatro chagásicos crônicos,
com pelo menos dois entre três testes sorológicos positivos para a
infecção, e 17 controles com testes sorológicos negativos formaram os
grupos de estudo. Os testes de PCR com primers de DNA de T. cruzi
monitoraram a eficácia do tratamento. Foram obtidos produtos de PCR
a partir de DNA de pacientes chagásicos tratados e não-tratados, com
primers de DNA nuclear de T. cruzi. Os produtos amplificados
hibridizaram com suas sequências internas e complementares. A técnica
de PCR competitiva foi usada para quantificar o número de parasitos no
sangue e revelou < 1 a 75 T. cruzi/ml em chagásicos não-tratados (média
25,83 ± 26,32) e < 1 a 36 T. cruzi/ml em chagásicos tratados (média
6,45 ± 9,28). A diferença entre as médias não foi estatisticamente
significativa. O resultado mostra que o tratamento da doença de Chagas
crônica com drogas nitroderivadas é insatisfatório.
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